DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • August 12th, 2014 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is effective as of May 1, 2014 (“Effective Date”), by and between Abbott Molecular Inc., a corporation organized under the laws of Delaware (“Abbott”), and Idera Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Idera”).
Amendment No. 1 to Exclusive License and Research Collaboration Agreement by and between Merck Sharp & Dohme Corp.and Idera Pharmaceuticals, Inc.Idera Pharmaceuticals, Inc. • August 12th, 2014 • Biological products, (no disgnostic substances)
This Amendment (“Amendment No. 1”) effective as of date or last signature (“Amendment No. 1 Effective Date”) confirms the mutual understanding between Merck Sharp & Dohme Corp. (“Merck”), and Idera Pharmaceuticals, Inc. (“Idera”) to amend certain terms and conditions of the Exclusive License and Research Collaboration Agreement between the Parties dated December 8, 2006, as modified by those certain letter agreements dated November 3, 2008, November 13, 2009, December 8, 2011, January 3, 2012, and January 6, 2012 (collectively, the “Agreement”).
